Ann: DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial, page-362

The problem with MSB at that stage is: this is taking too long

about 1.00 was the raised as Covid trial.
the process is so ling that now 2 vaccines with 95% effective become available in next 3 months and they will start with exactly the most vilnareble.

the size of potential market for ARDS - Covid is x% less every single day we postpone the final approval.

i feel is a shame how FDA is acting because if 1% better they should announce and authorised under compassionate usage and go ahead with trial.

the only reason acceptable( in my opinion) if they found the rem-l effectiveness is not good at all ( what could invite ask and how mt sinai trial was so good?)

every day we are closing to 1- 1.50 plus or 1-1.50 less. Really hard game ( and scary)

good luck if i are holding

CATO